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The Kennedy peptide, 731PRGPDRPEGIEEEGGERDRDRS752, from the cytoplasmic domain of the gp41 transmembrane
envelope glycoprotein of HIV-1 contains a conformationally dependent neutralizing epitope (ERDRD) and a linear nonneu-
tralizing epitope (IEEE). No recognized murine T cell epitope is present. The peptide usually stimulates virus-specific
antibody, but this is not always neutralizing. Here we show that IEEE (or possibly IEEE plus adjacent sequence) is
immunogenically and antigenically dominant over the ERDRD neutralizing epitope. Thus rabbits immunized in a variety of
routes, doses, and adjuvants with a chimeric cowpea mosaic virus (CPMV) expressing the Kennedy peptide on its surface
(CPMV-HIV/1) synthesized IEEE-specific serum antibody but no ERDRD-specific or HIV-1-neutralizing antibody. To test if this
resulted from immunodominance or from a hole in the antibody repertoire, we immunized rabbits with chimera CPMV-HIV/29,
which expresses the GERDRDR part of the Kennedy sequence. This chimera readily stimulated ERDRD-specific, neutralizing
antibody. In mice the situation was less extreme, but individual animals with low neutralizing titers had a high ratio of
IEEE-specific:ERDRD-specific antibody. Data are consistent with immunodominance of IEEE over ERDRD in the Kennedy
peptide. IEEE-specific antibody was also antigenically dominant and prevented ERDRD-specific antibody from binding to its
epitope and from neutralizing HIV-1. It may be that HIV-1 has evolved a nonneutralizing immunodominant epitope that allows
it to possess a neutralizing epitope without suffering the consequences, and this idea is supported by the covariance of both
epitope sequences. To our knowledge this is the first example of a defined sequence that controls the activity of an adjacent
epitope. © 2000 Academic Press
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Individuals infected with HIV-1 develop a neutralizing
antibody response which is directed against epitopes of
the gp120 and gp41 surface glycoproteins. Two major
seroreactivity regions of gp120, the V3 loop region and
the CD4 binding site, correlate closely with virus neutral-
izing ability and two more are located on the transmem-
brane protein, gp41. One is found in the extracellular
domain of gp41 at residues 662–667 (Muster et al., 1993;
Sattentau et al., 1995). The other is controversially lo-
cated in a supposedly intravirion position at residues
731PRGPDRPEGIEEEGGERDRDRS752 of gp41 (Modrow et
al., 1987; Gallagher et al., 1992). The ability of the latter to
function as a neutralization site is also a matter of debate
(Dalgleish et al., 1988; Sattentau et al., 1995). However,
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6our laboratory has recently clarified these issues and
has unequivocally demonstrated (see Discussion) that
the Kennedy peptide is expressed on the exterior of free
infectious virus particles (S. M. Cleveland, T. D. Jones,
and N. J. Dimmock, in preparation). In addition, as out-
lined below, it does contain a neutralizing epitope.
The antigenic properties of the gp41 region, residues
731–752, were first described in 1986 (Kennedy et al.,
1986). Several groups have obtained neutralizing anti-
bodies by conventional means, by using synthetic pep-
tides (Chanh et al., 1986; Dalgleish et al., 1988) or various
antigen-presenting systems (Evans et al., 1989; McLain
et al., 1995, 1996a, b; Newton et al., 1995), while others
failed to elicit neutralizing antibody (Pincus et al., 1993;
Kalyan et al., 1994). Only weakly or nonneutralizing mAbs
have been obtained (Dalgleish et al., 1988; Evans et al.,
1989; Niedrig et al., 1992; Pincus et al., 1993; Vella et al.,
1993). In infected individuals the antibody response to
this region is weak or nonexistent (Davis et al., 1990;
Goudsmit et al., 1990; Vella et al., 1991; Broliden et al.,
1992; Niedrig et al., 1992; Pincus et al., 1993). Human and
chimpanzee vaccinees immunized with gp160 re-
sponded strongly with antibodies against gp41 residues
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67IMMUNOSUPPRESSION OF A NEUTRALIZING EPITOPE731–752, but these did not correlate with virus neutral-
ization (Pincus et al., 1993, 1994). The isolation of a
nonneutralizing mAb from mice immunized in the same
way also suggested that this epitope was functionally
irrelevant (Pincus et al., 1993), although some nonneu-
tralizing MAbs had low infectivity-enhancing activity
(Niedrig et al., 1992). Recently, however, two epitopes
have been mapped in the Kennedy peptide to the se-
quences IEEE and ERDRD (Vella et al., 1993), and we
have subsequently demonstrated that the antibody re-
sponse to the Kennedy peptide is directed principally
against the linear IEEE epitope and that these antibodies
are not neutralizing. A third epitope, PRDPEG, is also
present but is only recognized on denatured antigen
(Abacioglu et al., 1994). All detectable neutralizing activ-
ity is directed against the conformationally dependent
ERDRD sequence (McLain et al., 1996a,b; Buratti et al.,
1998).
The observation that there is a linear, nonneutralizing
epitope (IEEE) adjacent to a neutralizing epitope with
strong conformational requirements (ERDRD) suggested
an explanation for the long-standing controversy over the
ability of gp41 731–752 to stimulate neutralizing antibod-
ies. Thus it might be that the proximity of these two
epitopes on gp41, separated by just two glycine residues,
resulted in immunogenic and/or antigenic interference,
by the nonneutralizing epitope and/or its cognate anti-
body, with the production and/or action of neutralizing
antibody. We have addressed the immunogenicity ques-
tion using a cowpea mosaic virus (CPMV) chimera that
expresses only the gp41 residues GERDRDR on its sur-
face. This was effective in stimulating neutralizing anti-
body in rabbits, which make no detectable antibody to
ERDRD when immunized with the Kennedy peptide ex-
pressed on the surface of a different CPMV chimera. In
addition we have demonstrated that IEEE-specific anti-
body blocks both the binding of ERDRD-specific antibody
in an ELISA format and the neutralization of HIV-1 infec-
tivity by ERDRD-specific antibody.
One hypothesis is that the IEEE or IEEE plus adjacent
sequence has evolved to specifically regulate the neu-
tralizing ERDRD epitope. To the authors’ knowledge, this
is the first example of removal of a natural epitope
improving the immunogenicity of a recombinant mole-
cule. Our work suggests that deletion of such specific
immunodominant epitopes will improve the immunoge-
nicity of vaccines designed to elicit neutralizing and
protective antibodies in vivo.
RESULTS
mmunogenicity of the ERDRD epitope in rabbits is
ompletely suppressed by the IEEE epitope
The Kennedy peptide (731PRGPDRPEGIEEEGGER-
752RDRS ) contains two major epitopes, a nonneutraliz-
ng, linear epitope comprising IEEE and the neutralizing
t
tonformational epitope ERDRD (Vella et al., 1993; McLain
t al., 1996a,b; Buratti et al., 1998; see above). Over
everal years we have been consistently able to raise
oth IEEE-specific and neutralizing antibodies in mice by
mmunization with the CPMV-HIV/1 chimera expressing
he gp41 Kennedy peptide 731–752 both subcutaneously
McLain et al., 1995, 1996a,b; McInerney et al., 1999) and
ntranasally (Durrani et al., 1998). Three different mouse
aplotypes all responded positively, and antisera neu-
ralized at dilutions up to 1/300 (McLain et al., 1996b).
abbits also responded strongly with high levels of
ennedy peptide-specific antibodies by ELISA, but with
o detectable neutralizing antibody. They also contained
igh titers of CPMV-specific ELISA antibodies (data not
hown). An example is shown in Figs. 1a–1c. The abso-
ute lack of detectable neutralizing antibody was consis-
ent in a total of five rabbits, despite varying parameters
f the immunization protocol, including the amount of
himera injected, the number of doses of chimera, the
oute (subcutaneous, intramuscular, intravenous), and
he adjuvant (alum or Freund’s complete) (Table 1). Titers
o the Kennedy peptide were driven to a high plateau
evel and could not be increased (data not shown).
Neutralizing ERDRD antibody cannot be assayed us-
ng solid-phase Kennedy peptide, as in this context the
RDRD epitope is not expressed in the correct confor-
ation. However, in the context of the chimeric flock
ouse virus fusion protein, FHV-L1-B (which expresses
ERDRDR), the ERDRD epitope is recognized by neutral-
zing ERDRD antibodies (Buratti et al., 1998). Nonethe-
ess, the GERDRDR epitope expressed by CPMV-HIV/1
as not immunogenic, as antisera raised to it did not
eact with FHV-L1-B (Fig. 1b), and this correlates with the
bsence of neutralizing antibody (Fig. 1c). Thus the an-
ibody reactivity in Fig. 1a would appear to represent
ntirely IEEE-specific antibody. Among the possible ex-
lanations were that the rabbits inherently lacked the
bility to respond to ERDRD, although this was unlikely
s they were outbred, or that the antibody response to
he ERDRD epitope was in some way suppressed. Ac-
ordingly, we made another chimera, CPMV-HIV/29, that
xpressed the GERDRDR part of the Kennedy peptide but
ithout the IEEE epitope and adjacent sequence. Rab-
its were then immunized with this chimera together with
lum adjuvant as before. After just two injections, these
abbits made antibody that recognized the conformation-
lly sensitive ERDRD epitope presented by FHV-L1-B
Fig. 1d) and was neutralizing (Fig. 1e). Thus we con-
luded that rabbits have the potential to respond to the
RDRD epitope and that this response is completely
brogated when ERDRD is presented on a peptide jux-
aposed to the IEEE epitope.
Mice differ from rabbits in that they are able to make
eutralizing antibody in response to CPMV-HIV/1, al-
hough the yields vary between experiments in a way
hat is not understood (references above). A comparison
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68 CLEVELAND ET AL.f antiserum pools from mice immunized with CPMV-
IV/1 and CPMV-HIV/29 is shown in Fig. 2. Mice receiv-
ng CPMV-HIV/29 gave .eightfold higher amounts of
RDRD-specific antibody and fivefold higher amounts of
eutralizing antibody.
ariable immunodominance of the IEEE epitope over
he ERDRD epitope in mice
Although we regularly obtain neutralizing antibody by
ubcutaneous immunization of mice with CPMV-HIV/1
McLain et al., 1995, 1996a, b; McInerney et al., 1999),
ome mice respond with only low levels of neutralizing
ntibody. One possible explanation is that the IEEE
pitope is antigenically dominant in these animals and
locks the binding of antibody to the ERDRD sequence,
rom which it is separated by only two glycine residues.
his was addressed by assays that measured the titer of
he conformationally dependent ERDRD-specific anti-
odies (using the FHV-L1-B protein that expresses GER-
RDR) and the titer of the antibodies to the linear IEEE
pitope (using the FHV-L2-A protein that expresses
FIG. 1. The serum antibody response in rabbits to the ERDRD epitop
n IEEE epitope situated to its amino terminus. Rabbits were immun
31PRGPDRPEGIEEEGGERDRDRS752 (a–c) or with CPMV-HIV/29 expres
ennedy peptide; (b and d) ELISA with solid phase FHV-L1-B protein
ssay of HIV-1cpmv/esc on C8166 cells. Subcutaneous immunization of rab
with CPMV-HIV/1, day 42 serum (F); subcutaneous immunization of ra
ith alum adjuvant (see Table 1 for immunization details). Assays were
ubtracted. Preimmune sera and sera from rabbits immunized with w
HV-L1-B ELISA, and ,20% in the neutralization assay.EEEGGERDRDR). The assay was validated using mAbs Specific for each epitope. Thus, mAb 1577 bound FHV-
1-B protein (Table 2, row 1, column c) but not to dena-
ured FHV-L2-A (Table 2, row 1, column b), and mAb 1575
ound both native and denatured FHV-L2-A protein (Ta-
le 2, row 1, columns a and b), but not to FHV-L1-A (Table
, row 2, column c). In addition, binding of affinity-purified
RDRD-specific IgG was reduced nearly 90% when a
enatured detecting antigen was used (data not shown).
o antibodies that recognized a linear version of epitope
RDRD were detected. Accordingly ERDRD-specific and
EEE-specific antibodies present in the same antiserum
rom mouse immunized with CPMV-HIV/1 could thus be
ssayed, and an example with two dilutions is shown in
able 2 (rows 3 and 4). In this case there was approxi-
ately the same amount of IEEE-specific and ERDRD-
pecific antibody. Table 3 summarizes the antibody ratios
f various neutralizing and nonneutralizing murine anti-
era. Antisera that neutralized by $70% had a ratio of
EEE-specific:ERDRD-specific antibodies ranging from
:1 to 7:1, whereas those having little or no detectable
eutralizing activity (#19%) ranged from 18:1 to 295:1.
gp41 Kennedy peptide is completely suppressed by the presence of
th CPMV-HIV/1 expressing on its surface the gp41 Kennedy peptide
its surface gp41 745GERDRDR751 (d and e). (a) ELISA with solid phase
resses the HIV-1 gp41 sequence GERDRDR; (c and e) neutralization
th CPMV-HIV/1, day 43 serum (}); intramuscular immunization of rabbit
with CPMV-HIV/29, day 28 serum (n). All immunogens were combined
out at least in duplicate. Values from preimmunization sera have been
gave background values: ,0.1 OD in the peptide ELISA, ,0.2 in thee of the
ized wi
sing on
that exp
bit 2 wi
bbit 10
carried
t CPMVignificantly, these ratios were independent of the abso-
incide,
69IMMUNOSUPPRESSION OF A NEUTRALIZING EPITOPElute antibody titers, with IEEE-specific antibody titers
from the neutralizing antisera ranging from 1/630 to
1/4,600 and those for the nonneutralizing antisera rang-
ing from 1/180 to 1/16,000. For example, antiserum 3,
with a low titer of both ERDRD-specific antibody (1/630)
and IEEE-specific antibody (1/630), gave 70% neutraliza-
tion, whereas antiserum 4, with a high titer of ERDRD-
specific antibody (1/4,500) and an even higher titer of
IEEE-specific antibody (1/16,000), did not neutralize.
Thus the data suggest that there is a trend for neutral-
izing activity to correlate positively with a higher propor-
Immunization of Rabbits
Rabbit No. Immunogen Route
1 CPMV wt sc A
2 CPMV-HIV/1 sc A
3 CPMV wt sc A
5 CPMV-HIV/1 sc A
6 CPMV-HIV/1 sc A
4 CPMV-HIV/1 sc, iv (day 122) A
7 CPMV wt im A
8 CPMV-HIV/1 im A
9 CPMV wt sc A
10 CPMV-HIV/29 sc A
11 CPMV-HIV/29 sc A
Note. FCA, Freund’s complete adjuvant. CPMV-HIV/1 expresses o
and CPMV-HIV/29 expresses 745GERDRDR751.
a Days of the injection/bleed; where injection and bleed days co
FIG. 2. Comparison of the secondary antibody response in pooled
731PRGPDRPEGIEEEGGERDRDRS752) or CPMV-HIV/29 (expressing gp41
neously with 10 mg of immunogen in alum on days 0 and 28 and bled from t
antibody measured using FHV-L1-B and (b) the 50% neutralization titers.tion of ERDRD-specific antibody and that IEEE-specific
antibodies interfere with the activity of ERDRD-specific
antibodies.
Binding of an ERDRD-specific mAb to gp41 peptide
741–751 is inhibited by the presence of an IEEE-
specific mAb
The suggestion above, that excess IEEE-specific anti-
bodies prevented the binding of ERDRD-specific antibod-
ies to virus, was explored in a competition assay using
an ERDRD-specific mAb (mAb 1577) and an IEEE-spe-
LE 1
PMV-HIV Chimeras or wt CPMV
juvant Injection (day)a Bleed (day)a
0, 37, 203 0, 43, 50, 57, 64, 210, 217
0, 37, 203 0, 43, 50, 57, 64, 210, 217
A (day 122) 0, 45, 122 0, 52, 59, 66, 73, 129, 136,
A (day 122) 0, 45, 122 0, 52, 59, 66, 73, 129, 136,
A (day 122) 0, 45, 122 0, 52, 59, 66, 73, 129, 136,
ne (day 122) 0, 45, 122 0, 52, 59, 66, 73, 129, 136,
0, 28 0, 14, 28, 42
0, 28 0, 14, 28, 42
0, 21 0, 28
0, 21, 49, 150 0, 28, 56, 157
0, 21, 75 0, 28, 82
rface the HIV-1 gp41 Kennedy peptide 731PRGPDRPEGIEEEGGERDRDRS
the bleed was made first.
f mice immunized with CPMV-HIV/1 (expressing the gp41 sequence
DRDR751). Mice (C3H/He-mg, H-2k; n 5 25) were immunized subcuta-TAB
with C
Ad
lum
lum
lum, FC 143
lum, FC 143
lum, FC 143
lum, no 143
lum
lum
lum
lum
lum
n its su 752,sera o
745GERhe heart on day 42. Shown are (a) the ELISA titers of ERDRD-specific
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70 CLEVELAND ET AL.cific mAb (mAb 1575). A saturating amount of biotinylated
mAb 1577 was mixed with various amounts of mAb 1575
and allowed to interact overnight in solution with solid
phase FHV-L2-A fusion protein expressing the gp41 pep-
tide IEEEGGERDRDR. Figure 3 shows that the binding of
mAb 1577 was significantly (25%) inhibited by the addi-
tion of 0.07 mg/100 ml/well of mAb 1575, and this inhibi-
ion increased to over 97% with 0.7 mg/100 ml/well of
Ab 1575. Thus a mAb specific to the IEEE epitope can
lmost completely suppress the binding of a second and
istinct mAb that recognizes an adjacent epitope (ER-
RD) from which it is separated by just two glycine
esidues.
eutralization of HIV-1cpmv/esc by ERDRD-specific
ntibody and inhibition of neutralization by the
resence of an IEEE-specific mAb
We have shown above that the presence of an excess of
EEE-specific antibodies in mouse antisera correlates with
ow neutralization titers and that in an ELISA format an
T
Assay of the Amount of Anti-IEEE and Anti-ERDRD IgG
Antibody
Native FHV-L2-A
(anti-IEEE 1 anti-ERDR
(a)
Anti-ERDRD (mAb 1577, 0.05 mg/100 ml/well) 1.87b
Anti-IEEE (mAb 1575, 0.007 mg/100 ml/well) 2.4
nti-CPMV-HIV/1 (1/3000) nd
nti-CPMV-HIV/1 (1/10,000) nd
Note. na, not applicable; nd, not done; FHV-L2-A protein expresses th
745GERDRDR751.
a Corrected by 5.9, the difference in the concentrations of mAb 1577
give approximately the same binding to antigen after overnight incubati
affinity-purified polyclonal antibody, 2.17 3 108 M21; IEEE-specific mAb 1
07 M21 (unpublished data).
b OD405.
T
Relationship between the HIV-1 Neutralization
in the Antisera of Mice
Antiserum
No.
Titer of
ERDRD-specific IgGa
Titer of
IEEE-specific IgGa
1 1600 4,600
2 2000 1,800
3 630 630
4 4500 16,000
5 ,300 180
6 ,300 5,600
7 400 8,000
a 1/Dilution that gave 0.5 OD405.
b With antiserum diluted 1/20; normal mouse serum caused #15% neutraliz
c See Table 2 for calculation of the ratios.EEE-specific mAb prevented the binding of an ERDRD-
pecific mAb. Here we examined the ability of the same
EEE-specific mAb (1575) to prevent neutralization of HIV-
cpmv/esc by incubation with polyclonal ERDRD-specific anti-
body affinity purified on FHV-L1-B from antiserum prepared
by immunization of mice with the CPMV-HIV/1 chimera. In
Fig. 4 we show that the addition of increasing amounts of
mAb 1575 progressively reduced the amount of observed
neutralization by more than 70% (Fig. 4). Thus an excess of
IEEE-specific antibody can drastically reduce the neutral-
ization of HIV-1 by ERDRD-specific antibody.
DISCUSSION
Proposed immunodominance of the IEEE sequence
The Kennedy peptide from the gp41 of HIV-1 can elicit
nonneutralizing as well as neutralizing antibodies, and
data presented above suggest that the nonneutralizing
IEEE epitope in the Kennedy peptide or IEEE plus adja-
cent sequence, expressed in the CPMV-HIV/1 chimera,
t in the Antisera of Mice Immunized with CPMV-HIV/1
enatured FHV-L2-A
(anti-IEEE)
(b)
Native FHV-L1-B
(anti-ERDRD)
(c)
Ratio
b/c
Ratio b/c corrected
(approx.)a
0.05 1.87 na na
2.25 0 na na
0.62 0.5 1.24:1 7.3:1
0.18 0.15 1.20:1 7.1:1
gp41 Kennedy peptide 740IEEEGGERDRDR751, and FHV-L1-B expresses
575 (30.05/0.007) and of their ODs (31.87/2.25) that were required to
nities were ERDRD-specific mAb 1577, 7.12 3 106 M21; ERDRD-specific
03 3 108 M21; IEEE-specific affinity-purified polyclonal antibody, 2.51 3
nd the Ratio of Anti-IEEE IgG:Anti-ERDRD IgG
ized with CPMV-HIV/1
tralization of
-1cpmv/esc (%)
b
Ratio of IEEE-specific:
ERDRD-specific antibodyc
Corrected ratio
(approx.)c
95 1.2:1 7:1
75 0.7:1 4:1
70 0.3:1 2:1
19 3:1 18:1
11 9:1 53:1
10 50:1 295:1
0 3:1 18:1ABLE 2
Presen
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71IMMUNOSUPPRESSION OF A NEUTRALIZING EPITOPEis immunodominant over the neutralizing ERDRD
epitope. In rabbits the situation is clear cut, as no neu-
tralizing antibody was detected at any time in five ani-
mals immunized variously with adjuvanted CPMV-HIV/1
by the subcutaneous or intramuscular routes or by the
intravenous route (Table 1; Fig. 1; unpublished data).
More surprisingly, no ERDRD-specific antibody was de-
tectable by ELISA using the FHV-L1-B protein that binds
both the conformation-dependent, neutralizing, ERDRD-
specific antibody and the nonneutralizing, ERDRD-spe-
cific mAb 1577. Thus in rabbits the immunodominance
over the ERDRD epitope was absolute. In mice the situ-
ation is less clear cut. We have immunized many batches
of mice with CPMV-HIV/1 and have always obtained a
neutralizing antibody response, but the magnitude of the
response varied between experiments. Mostly we used
alum adjuvant and the subcutaneous route, but we have
also used Quil A, Freund’s, Ribi, and Adjuprime adjuvants
(McInerney et al., 1999) and nasal and oral inoculation
with and without cholera toxin (Durrani et al., 1998). The
response, with or without adjuvant, as measured by
reaction with solid phase Kennedy peptide (i.e., IEEE-
specific antibody) is solidly Th1 in character, as judged
by a predominance of HIV-1-specific IgG2a (McInerney
et al., 1999). However, earlier studies showed that both
eutralizing and nonneutralizing antibodies were being
timulated (McLain et al., 1996b). Here we have pre-
ented data suggesting that in mice the ratio of nonneu-
ralizing:neutralizing antibodies varies and that there is
FIG. 3. Inhibition of binding of the ERDRD-specific mAb 1577 (1.35
mg/100 ml/well) to the fusion protein FHV-L2-A, which expresses the
IV-1 gp41 sequence IEEEGGERDRDR, in the presence of increasing
mounts of the IEEE-specific mAb 1575. MAb 1577 was biotinylated
nd detected by incubation with streptavidin-linked alkaline phospha-
ase MAb 1577 bound to FHV-L2-A to $93% in the presence of amounts
f up to 0.7 mg/100 ml/well of normal mouse IgG (data not shown).n inverse correlation between the IEEE-specific non-
eutralizing antibody and the neutralizing ERDRD-spe-cific antibody (Table 3). Thus, in addition to immunogenic
dominance of the IEEE epitope, an excess of IEEE-
specific antibody appears to inhibit neutralization of
HIV-1 by ERDRD-specific antibody. What causes this ra-
tio to vary is not known.
To test the imputed immunodominance of the IEEE
epitope, we constructed a chimera expressing a trun-
cated form of the Kennedy peptide which contained only
the sequence GERDRD of gp41. In a startling reversal of
the situation with the Kennedy peptide, rabbits immu-
nized with this chimera made both neutralizing antibody
and ERDRD-specific antibody (Figs. 1d and 1e). Another
chimera (CPMV-HIV/30) that expresses a dimer of ER-
DRD also stimulated antibodies of the same character in
rabbits and in mice (data not shown). In addition the
levels of ERDRD-specific and neutralizing antibodies
stimulated in mice by CPMV-HIV/29 were significantly
increased over those made in response to CPMV-HIV/1
(Fig. 2). However, proof that the IEEE epitope is immu-
nodominant must await further verification, in view of
data showing that even subtle differences of one or two
amino acids in epitope flanking sequences can influence
the immunogenicity of B cell epitopes (Vijaykrishnan et
l., 1997).
In the mouse the immunodominance of the IEEE (and
ossibly adjacent) sequence appeared to relate solely to
umoral immunity, as the Kennedy peptide stimulated no
cell proliferation (McInerney et al., 1999) and contained
none of the MHC binding sequences found in the MH-
FIG. 4. Inhibition of the neutralization HIV-1cpmv/esc by affinity-purified
polyclonal ERDRD-specific antibody in the presence of the IEEE-spe-
cific mAb 1575. The ERDRD-specific antibody from the serum of mice
immunized with CPMV-HIV/1 was purified by adsorption and elution
from FHV-L1-B protein. Increasing amounts of mAb 1575 and 0.1 mg
polyclonal ERDRD-specific antibody were mixed with HIV-1cpmv/esc and
incubated for 1 h at 37°C before inoculating onto C8166 cells. Cells
were then incubated for 3 days and syncytia counted. Neutralization is
expressed as the percentage reduction of syncytia with reference to
virus incubated in the absence of antibody. Replacement of mAb 1575
with normal mouse IgG gave no reduction in neutralization, and mAb
1575 alone gave no neutralization.
72 CLEVELAND ET AL.CPEP database (Brusic et al., 1994). At present, we have
no information about how the IEEE sequence interacts
with the immune system. Its effect appears to be epitope-
specific, as synthesis of antibodies to IEEE itself or to
epitopes of the CPMV carrier particle was not inhibited
and thus differs from the action of a Kennedy peptide that
caused general suppression of human and murine lym-
phocyte blastogenesis (Chanh et al., 1988).
The phenomenon of immunodominance in viruses
other than HIV-1
Immunodominance of a nonneutralizing epitope over a
neutralizing epitope appears to be an immune response-
evasion strategy commonly found in viruses, bacteria,
protozoa, parasitic agents, and cancer cells (Garrity et
al., 1997). During HIV-1 infection there is a strong anti-
body response against the envelope glycoproteins and
internal viral proteins, but the response is nonneutraliz-
ing and may even facilitate viral infection (Karpatkin et
al., 1988; Levy, 1998). This nonneutralizing response may
be related to the overall composition of the HIV-1 ge-
nome, which is unusually rich in A and G and deficient in
U and C nucleotides (Fitzgerald et al., 1996). This nucle-
otide bias is the major factor in determining the unusual
composition of HIV-1 proteins, which are deficient in
proline and rich in lysine and other polar residues. Such
proteins have also been found as the immunodominant
surface antigens of many human pathogens, indicating a
possible common strategy for the promotion of immune
dysregulation (Fitzgerald et al., 1996). HIV-1 contains at
least two other immunodominant regions, the V3 region
of gp120 (Garrity et al., 1994) and residues 600–611 on
gp41 (Gnann et al., 1987; Mathiesen et al., 1989), which
are thought to prevent the development of an effective
anti-viral antibody response (Fitzgerald et al., 1996).
The mechanism by which immunodominance prevails
is not fully understood. One view is that special structural
properties intrinsic to certain regions of a protein make
these regions immunodominant (Benjamin et al., 1984;
Kumar et al., 1994). This could include the accessibility of
epitopes for B or T cell recognition. Thus, if the IEEE
sequence is more accessible for binding, this would bias
the immune response away from the ERDRD epitope.
Alternative views point more toward the regulatory pro-
cesses of the host. These include the host’s previous
exposure to similar epitopes on unrelated antigens. For
example, immunodominance of the 600–611 region of
HIV-1 gp41 could be caused by memory cells in the
patient produced by prior exposure to a similar epitope
during infection with a rhinovirus (Davis et al., 1990).
Other theories include the action of T cells that guide B
cell fine specificity (Berzofsky et al., 1979) competition
among B lymphocytes with the same or different fine
specificities (Kunkl et al., 1992), and regulation byepitope-specific T cell suppressor cells (Gajewski et al.,
1989).
Selective masking of epitopes by antibody has been
described (Manca et al., 1988) and involves properties of
both the immunogen and the host response. This could
work in several ways. First, if the host already has anti-
body to the ERDRD epitope due to some previous expo-
sure, this will bind to the ERDRD epitope of CPMV-HIV/1
when the host is immunized. As an epitope complexed
with an antibody cannot be recognized by the cognate B
cell receptor, there will be no upregulation of ERDRD-
specific antibody production, and an antibody response
to other epitopes (like IEEE) may be favored. However,
this is unlikely to apply to our data, as preimmune rabbit
sera contained no detectable ERDRD-specific antibody.
Second, if binding of the IEEE epitope to a B cell or
antigen-presenting cell physically masks the ERDRD
epitope, so that it is no longer available for binding to
ERDRD-specific receptors, this would bias the immune
response toward the IEEE epitope. This effect could be
further increased if the IEEE-specific B cell receptors
have greater affinity for the IEEE epitope than the ER-
DRD-specific B cell receptor does for its cognate
epitope. Third, if IEEE-specific antibody was synthesized
more rapidly than ERDRD-specific antibody, it could bind
to the gp41 peptide and physically prevent the recogni-
tion of ERDRD by its cognate B cell.
One other explanation for the immunodominance of
the IEEE epitope arises from a modification (Bachmann
and Zinkernagel, 1997) of the two-signal theory for B cell
activation versus induction of B cell tolerance (Bretscher
and Cohn, 1970), which proposes that B cells are acti-
vated only in the presence of antigen (signal 1) and a
concomitant second signal (signal 2). However, signal 1
alone can stimulate naı¨ve B cells to produce IgM and
memory cells if the epitopes are repeated and close
together (5–10 nm), as they are on viruses like picorna-
viruses and orthomyxoviruses (Bachmann and Zinkerna-
gel, 1996, 1997). Signal 1 alone usually induces B cell
tolerance, but if signal 1 is strong enough (i.e., there is
efficient B cell receptor cross-linking) it can induce B cell
activation (Bachmann and Zinkernagel, 1997). In our ex-
periments, antiserum from rabbit 4 made no IEEE-spe-
cific antibody and had no HIV-1 neutralizing activity at 14
days postimmunization with CPMV-HIV/1, suggesting
that no ERDRD-specific IgM or IgG had been produced.
At 28 days postimmunization, antiserum was still non-
neutralizing, but IEEE-specific IgG was present (T. L.
McInerney, personal communication). Thus it seems that
IEEE activates cognate B cells and that the responsive-
ness of ERDRD-specific B cells is specifically abrogated.
One way this might be achieved is by IEEE binding
nonspecifically, possibly through its strong negative
charge, to complementary regions of the ERDRD-cog-
nate B cell, sending a signal that directly or indirectly
overwhelms signal 1.
73IMMUNOSUPPRESSION OF A NEUTRALIZING EPITOPEThe high glutamate content of IEEE may also be sig-
nificant to its proposed immunodominance, as a peptide
(peptide 1) with a high content of glutamic acid residues
generated clonal dominance of B cells after primary
immunization of mice (Ju et al., 1993). Peptide-1-primed B
cells captured and processed peptide 2 (which con-
tained peptide 1 plus some additional sequence) effi-
ciently. This activated T-helper cells, which in turn
caused the differentiation of plasma cells secreting anti-
peptide 1 antibodies.
Another aspect of this complex area of immunodomi-
nance is the demonstration that the relative immu-
nodominance of a peptide B cell epitope is independent
of the conformational constraints imposed on it and its
overall immunogenicity (Nayak et al., 1998). Additionally
in this system, antigen-dependent repertoire discrimina-
tion appeared to be regulated by the rapidity of binding
rather than by the stability of binding.
Antigenic dominance of IEEE-specific antibody and
properties of ERDRD-specific antibody
The conclusion that the relative proportions of IEEE-
specific and ERDRD-specific antibodies in mouse serum
control neutralization efficiency was supported by recon-
struction experiments in which we found that IEEE-spe-
cific antibodies prevented the binding of ERDRD-specific
antibodies to the native form of the fusion protein FHV-
L2-A (Fig. 3). Furthermore, similar mixtures using the
affinity-purified ERDRD-specific polyclonal antibody from
serum of mice immunized with CPMV-HIV/1, and mAb
1575 to the IEEE epitope, demonstrated that the latter
blocked neutralization of infectious HIV-1. Thus, our con-
clusions of immunogenic and antigenic dominance of
IEEE are valid not only for the epitope in various peptide
formats but also for HIV-1 itself. However, quantitative
comparisons of the relative amounts of IEEE-specific and
ERDRD-specific antibodies required for antigenic domi-
nance are not possible because of differences in the
format of antigens and affinities of antibodies used in the
various assays.
So far the literature contains no conclusive evidence
that ERDRD-specific antibodies bind to the ERDRD
epitope in the gp41 protein of infectious HIV-1, and in fact
this has been disputed (Sattentau et al., 1995). However,
data to be presented elsewhere demonstrate that a de-
letion mutant lacking most of the intravirion gp41 tail
does not bind ERDRD-specific antibody and is not neu-
tralized (S. M. Cleveland and N. J. Dimmock, unpublished
data). This implies that the Kennedy peptide is exposed
on the surface of the virion, a fact supported by (a) the
binding of ERDRD-specific antibodies to free HIV-1 par-
ticles in solution, (b) their neutralization after unbound
antibody has been separated from virus–antibody com-
plexes, and (c) the failure of ERDRD-specific antibodies
to bind to protease-treated virions. As yet we do notknow what event in the infectious process is interrupted
by ERDRD-specific antibodies to cause neutralization,
but when elucidated such data will give new insights into
the structure–function relationships of the virus.
In principle interference in the binding of antibodies to
neighboring epitopes, such as IEEE and ERDRD, de-
pends on proximity of those epitopes and the orientation
of those antibodies. The known size of the antibody
footprint and the fact that IEEE and ERDRD are sepa-
rated by only two glycine residues means that, if their
respective antibodies bind in the same orientation, their
footprints (Amit et al., 1986; Wilson and Stanfield, 1993)
are likely to overlap and there would be interference. If,
on the other hand, the antibodies bound on opposite
sides of the peptide there might be little interference, as
shown for two mAbs to the hemagglutinin of influenza
virus that bound simultaneously to epitopes that were
separated by just three amino acid residues (Jackson et
al., 1988).
As a result of this study, much of the confusion sur-
rounding the Kennedy peptide has been resolved. We
know that it contains a neutralizing epitope, and that the
antibody made in response to CPMV-HIV/1 is highly
active is shown by its affinity (Table 2) and neutralization
rate constant, the third highest of all those we have
tested (Krause et al., 1997; unpublished data). In addition
we can now explain the failure of recombinant gp160 to
induce neutralizing responses against this region (Pin-
cus et al., 1993, 1994), as rgp160 in solution does not bind
neutralizing ERDRD-specific antibody, presumably as it
lacks the required conformation (S. M. Cleveland and
N. J. Dimmock, unpublished data). Such data underline
that the CPMV chimeras have the ability to present
epitopes in their required biologically active conforma-
tion and have already proved to be efficient vaccines in
vivo (Dalsgaard et al., 1997). In addition and surprisingly,
CPMV-HIV/29 did not elicit the synthesis of any nonneu-
tralizing ERDRD-specific antibodies that were able to
bind to free gp41 peptide 731–752.
Immune evasion by HIV-1
The envelope protein of HIV-1 has evolved a number of
different ways of evading the immune system and par-
ticularly of evading neutralizing antibodies (Sattentau,
1998). These include extensive glycosylation of both
gp120 and gp41 subunits and the evolution of hypervari-
able loops that can vary under immunological pressure,
without affecting essential functions. The variable loops,
V1 and V2, partly mask the binding site for the primary
virus receptor, CD4, and may attract or decoy the im-
mune response away from other epitopes less able to
vary (Garrity et al., 1994, 1997). The binding of CD4
induces a variety of conformational changes that allow
succeeding events leading to fusion and entry of the
virus genome into the target cell to take place. The CD4
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74 CLEVELAND ET AL.binding site is recessed, which makes it physically diffi-
cult for an antibody paratope to make contact with it. In
addition, the CD4 binding site is an invariant region that
is intrinsically unable to sustain amino acid replace-
ments. However, it contains hydrophilic residues lining
the cavity that make no contact with CD4 and are subject
to mutation. Another form of evasion is the release from
the infected cell of large amounts of monomeric gp120
that have highly immunogenic surfaces that are oc-
cluded in the mature trimer. Antibodies made to these
surfaces are not antiviral, and monomeric gp120 has
been regarded as another type of immunological decoy
(Burton, 1997). The net result of all these effects is that
the mature HIV-1 envelope contains a highly nonimmu-
nogenic protein, which stimulates few antibody specific-
ities that pose any danger to the virus, and is relatively
nonreactive to those few defined antibodies (b12, 2G12,
and 2F5; Burton, 1997) that are capable of cross-neutral-
izing primary strains belonging to different clades. Our
discovery of an immunosuppressive/immunodominant
epitope that specifically controls an adjacent neutralizing
epitope adds a new mechanism of evasion to this al-
ready long list.
One interpretation of our data is that the nonneutral-
izing epitope IEEE has evolved so that the virus can
possess the ERDRD sequence, which is also a neutral-
izing epitope, with relative impunity. This implies that
ERDRD is functionally important to the virus. At the same
time it can be argued that if the ERDRD sequence had
constraints that prevented it from undergoing mutation, it
would be predicted to be relatively invariant. Further, if
the function of IEEE is to dominate the antibody re-
sponses to ERDRD, it too would be expected to be
invariant. Such predictions are borne out by the facts that
ERDRD is 81% conserved and IEEE is 87% conserved in
31 strains of clade B. Conversely, where ERDRD is not
conserved in any of 14 strains from clades A (4), C (1), D
(5), E (1), and O (3), IEEE is only 43% conserved (Myers et
al., 1993).
To our knowledge the IEEE sequence is the first ex-
mple of an epitope that may have evolved to specifically
uppress a neutralizing epitope. It may be that this is not
nique either in HIV-1 or in other viral antigens, and it
ay be useful to scrutinize any vaccine that fails to elicit
n expected neutralizing antibody response for the pres-
nce of a defined immunodominant epitope, though not
ecessarily IEEE, that can be deleted to beneficial effect.
n this regard it is worth noting that no immunogen is
nown that can raise the b12, 2G12, and 2F5 antibody
pecificities that are active against primary virus strains
elonging to different clades (Burton, 1997), although the
ognate epitope is present and available to react with
ntibody in several different forms of the immunogen.
ur clarification of the immunology of the Kennedy pep-ide, as well as the provision of antigens that permit the
ssessment of specific IEEE and neutralizing ERDRD-
wspecific antibodies by ELISA, now allows the situation in
human infection to be reassessed. Any role for ERDRD-
specific antibody epitope in potential vaccines remains
to be determined. The epitope is conserved and if ER-
DRD-specific antibody proves to neutralize and protect
against primary strains of virus, an immunogen like
CPMV-HIV/29 might prove useful prophylactically or even
therapeutically.
MATERIALS AND METHODS
Viruses
Preparation of CPMV chimeras expressing foreign
peptides has been described previously (Porta et al.,
1994; Dalsgaard et al., 1997). CPMV is a plant comovirus
with a genome consisting of two molecules of plus
sense, single-stranded RNA. Both have been cloned on
separate plasmids downstream of the cauliflower mo-
saic virus 35S promoter. Plasmid pCP2-0.51 contains
RNA 2, which encodes for the two virus coat protein
molecules, S and L. In this plasmid the S protein is
modified to contain a peptide from human rhinovirus
(HRV) such that it is expressed on the outer surface of
the CPMV chimera. For this study the HRV sequence was
removed and replaced by oligonucleotides encoding
peptides from the gp41 transmembrane protein of HIV-1
strain IIIB. The chimeric virus CPMV-HIV/1 expresses the
peptide 731PRGPDRPEGIEEEGGERDRDRS752 and CPMV-
HIV/29 expresses 745GERDRDR751. Infectious virus was
obtained by transfecting leaves of 10-day-old cowpea
plants (Vigna unguiculata var. blackeye) with either of the
above linearized RNA 2 constructs mixed with linearized
cDNA of CPMV RNA 1 (pCP1). Virus propagation and
purification were carried out as previously described
(Dalsgaard et al., 1997). Purified virus was filtered
through a 0.2-mm membrane and dialyzed against PBS
efore inoculation of animals. Virus concentration was
etermined by the Biorad assay (Bio-Rad Laboratories
mbH, Munich, Germany). Each virion expresses 60
opies of the HIV-1 gp41 peptide, and 1 mg of the CPMV-
IV/1 and CPMV-HIV/29 chimeras contains approxi-
ately 17 and 6 ng, respectively, of gp41 peptide.
One problem in measuring HIV-1-specific antibody
roduced in response to CPMV-HIV chimeras is that
IV-1 IIIB is specifically neutralized to a low extent by
ntibodies to wt CPMV (McLain et al., 1995). To avoid this
omplication we prepared an escape mutant by six serial
assages of HIV-1 IIIB in the presence of CPMV-specific
gG, followed by limit dilution cloning and screening for
esistance to the selecting antibodies (S. M. Cleveland
nd N. J. Dimmock, unpublished data). The escape mu-
ant selected, HIV-1cpmv/esc, was completely resistant to
eutralization by antisera to wt CPMV and was used
hroughout this study. A chronic infection of H9 T cells
as set up with HIV-1cpmv/esc, and stocks of virus were
prepared in the usual way by cocultivation with unin-
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75IMMUNOSUPPRESSION OF A NEUTRALIZING EPITOPEfected H9 cells. Cells were incubated for 3 days at 37°C
and placed in fresh medium 24 h before harvesting. TCFs
were clarified by low-speed centrifugation and stored in
the vapor phase of liquid nitrogen.
Cells
The human T cell lines H9 and C8166 were main-
tained at 37°C in a humidified atmosphere of 5% CO2
in air. Cells were grown in RPMI medium without
antibiotics (Gibco BRL, Life Technologies, Scotland),
but supplemented with 2 mM glutamine and 10% v/v
heat-inactivated fetal calf serum (LabTech Int., East
Sussex, UK).
Antibodies
MAbs 1575 and mAb 1577 specific for epitopes IEEE
and ERDRD, respectively, were kindly donated by Dr. C.
Vella (NIBSC, Potters Bar, UK). Polyclonal ERDRD-spe-
cific antibody from antiserum was affinity purified using
nitrocellulose-immobilized flock house virus-L1-B (FHV-
L1-B) protein that contains the gp41 sequence 745GER-
RDR751 in its native conformation (Buratti et al., 1998;
see below).
Immunization of mice and rabbits with CPMV-HIV/1,
CPMV-HIV/29, and wt CPMV
Adult C3H/He-mg mice (H-2k), which were bred in-
house, were immunized at 6–8 weeks of age (McLain
et al., 1995). Briefly wt CPMV or the chimeras CPMV-
HIV/1 or CPMV-HIV/29 were mixed with aluminium
hydroxide adjuvant (Imject Alum, Pierce & Warriner
Ltd., Chester, UK) at a ratio of 1:4 and injected subcu-
taneously in several sites on days 0 and 28 with 100 ml
ontaining 10 mg virus. Blood was obtained from the
heart 14 days after the last injection. Additional anti-
sera were obtained from other mice immunized with
CPMV-HIV/1 (McInerney et al., 1999). In all 11 outbred
half-lop rabbits (Froxfield Farms UK Ltd., Petersfield,
UK; Harlan UK Ltd., Bicester, UK) were immunized at 6
weeks of age, as detailed in Table 1. Eight rabbits were
immunized with various doses of CPMV-HIV/1 chimera
or wt CPMV (100–1250 mg). Six were injected subcu-
taneously and two were injected intramuscularly, all in
several sites. After subcutaneous injection, rabbits
were immunized further with virus in Freund’s com-
plete adjuvant and or intravenously without adjuvant.
Serum samples representative of the secondary anti-
body response were taken from an ear vein at various
times after the booster injection (Table 1), but were
also taken from the animals immunized intramuscu-
larly to examine the primary response. Two rabbits
were immunized subcutaneously with an intermediate
dose (500 mg) of CPMV-HIV/29 in alum. All antisera
ere heated at 56°C for 30 min and stored at 270°C.
w
RHV-gp41 fusion proteins and a gp41 synthetic
eptide
The fusion protein FHV-L1-B contains the HIV-1 gp41
equence 745GERDRDR751, and FHV-L2-A contains the
p41 sequence 740IEEEGGERDRDR751. Both proteins
ere produced in Escherichia coli strain BL21 using a
ET expression system and purified by electroelution
rom SDS–PAGE gels (Buratti et al., 1996). The synthetic
p41 peptide 731PRGPDRPEGIEEEGGERDRDRS752 was
obtained from Alta Bioscience (University of Birmingham,
Birmingham, UK).
ELISAs with FHV-L1-B and peptides
Wells of an ELISA microplate (Immulon 2; Dynex
Laboratories, Billinghurst, UK) were coated with pro-
tein or peptide solutions (1 mg/ml; 100 ml/well used
throughout) in 200 mM NaHCO3, pH 9.6, and held
overnight at 4°C. Following washing with Tris-buffered
saline (TBS; 0.14 M NaCl, 0.02 M Tris buffer, pH 7.6),
nonspecific sites were blocked with TBS containing
2% BSA (Sigma, Poole, UK) for 2 h at room temperature
(RT). MAb or antiserum was diluted in TBS containing
0.05% Tween 20 (TBST) and 0.5% BSA and 100 ml
added to washed wells. After an overnight incubation
at 4°C, plates were washed with TBST and biotinyl-
ated anti-species IgG (Amersham Life Science Ltd.,
Amersham, UK) was added for 2 h at RT. Wells were
washed with TBST. Streptavidin-linked alkaline phos-
phatase (SAP; Amersham Life Science Ltd.) was
added for 1 h at RT, and wells were washed and
eveloped using substrate [p-nitrophenyl phosphate, 1
g/ml (Sigma)] in diethanolamine, 0.5 M magnesium
hloride, pH 9.8 (Pierce & Warriner Ltd.). Plates were
ncubated at 37°C in the dark and then the OD was
easured at 405 nm.
ssay of HIV-1-neutralizing antibody
Neutralization assays were performed using an ad-
ptation of a syncytium-inhibition assay (McLain and
immock, 1994). Dilutions of antibody were incubated
ith 1000 syncytium forming units (SFU) of HIV-1cpmv/esc
in 550 ml for 1 h at 37°C. This was then incubated with
C8166 cells (2 3 105 in 50 ml) for 1 h 37°C to allow
nfection to take place. Cells were washed, resus-
ended in 1 ml, and aliquotted in 200-ml volumes.
hese were incubated for 3 days at 37°C, before
ounting syncytia under the microscope. Neutraliza-
ion was calculated as the percentage of reduction in
FU in wells containing antibody compared to the
irus control. Competition neutralization assays were
erformed by mixing 50 ml virus with 500 ml of a
onstant amount of ERDRD-specific antibody into
hich IEEE-specific mAb 1575 had been diluted (see
esults for further details). Controls of ERDRD-specific
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76 CLEVELAND ET AL.antibody alone, mAb 1575 alone, and normal mouse
IgG were also carried out. Neutralization by the latter
was always ,20%.
Inhibition of the binding of ERDRD-specific mAb 1577
to FHV-L2-A protein by IEEE-specific mAb 1575
Microplate wells were coated with 0.1 mg/100 ml/
ell of FHV-L2-A and then blocked as described
bove. MAb 1577 was biotinylated according to the
anufacturer’s instructions (Pierce & Warriner Ltd.).
iotinylated mAb 1577 (1.3 mg/100 ml/well) was mixed
with varying amounts of mAb 1575 in TBST containing
0.5% BSA. MAb mixtures were then added to the FHV-
L2-A-coated wells and held overnight at 4°C. After
washing with TBST, any bound mAb 1577 was de-
tected by the addition of SAP and substrate as de-
scribed above.
Determination of the ratio of IEEE-specific antibody:
ERDRD-specific antibody in antisera obtained from
mice immunized with CPMV-HIV/1
Titration showed that 3 mg/100 ml/well of FHV-L1-B
protein and 0.1 mg/100 ml/well of FHV-L2-A protein
ere required to bind 0.05 mg/100 ml/well of the ER-
RD-specific antibody mAb 1577 during an overnight
ncubation. The difference probably resided in differ-
nces in conformation since ERDRD-specific mAbs
ave conformation-dependent epitopes (Buratti et al.,
996). The same difference in antigen binding was
een also with ERDRD-specific polyclonal antibody
aised to CPMV-HIV/1 (Buratti et al., 1998; S. M. Cleve-
and, unpublished data). In contrast, IEEE-specific
Ab bound equally well to native and denatured FHV-
2-A protein, indicating that it has no conformational
equirement for binding. This was also the case for
EEE-specific polyclonal antibody raised to CPMV-
IV/1 (Buratti et al., 1998; S. M. Cleveland, unpub-
ished data). To assay the ERDRD-specific and IEEE-
pecific antibodies present in antiserum, we coated
alf of a 96-well microplate with 0.1 mg/100 ml/well of
enatured FHV-L2-A protein (boiled for 5 min in car-
onate buffer, pH 9.6, containing 1% SDS and 50 mM
ithiothreitol) and the other half with 3 mg/100 ml/well
ative FHV-L1 B protein. Antisera were heat-inacti-
ated before use and were diluted in TBST containing
.5% BSA and incubated in the plate overnight at 4°C.
ositive reactions were determined as described
bove. Controls demonstrated the ability of ERDRD-
pecific antibody (mAb 1577) to bind to native FHV-
2-A and FHV-L1-B and its inability to bind to dena-
ured FHV-L2-A. A second set of controls showed that
EEE-specific antibody (mAb 1575) recognized both
ative and denatured FHV-L2-A. From these data, theatios of IEEE-specific:ERDRD-specific antibody in an-
isera raised to CPMV-HIV/1 were calculated (see Re-ults). Binding by normal mouse IgG or of IgG from
ice immunized with wt CPMV was ,0.1 OD.
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